DRG Market Assessment reports

  Affecting more than 3 million people in the major pharmaceutical markets, moderate to severe psoriasis represents a large market with substantial commercial potential. Significant…

Postherpetic neuralgia (PHN) has served—and continues to serve—as a gateway indication into the lucrative neuropathic pain (NP) therapy market. Drugs such as Pfizer’s Lyrica (pregabalin),…

The biosimilars space is expected to become increasingly competitive as reference brand companies try to retain market share in the face of their product’s dwindling patent life and biosimilar…

Each year in the United States, more than 17,000 patients suffering from renal failure undergo a kidney transplant. To prevent rejection and maintain the new kidney’s functionality, these…

Multiple sclerosis (MS) is a dynamic therapy market in the United States with 12 branded (and 1 generic) disease-modifying therapies (DMTs) boasting unique balances of efficacy, safety, and…

Metastatic squamous-cell NSCLC is an incurable disease associated with a dismal 5 year OS of

Introduction Oncology is increasingly moving toward a personalized treatment approach, enlisting predictive biomarkers to guide therapy choice. This trend is already being felt in indications as…

The CurrentTreatment Bone and Mineral Metabolism (BMM) disorders content examines the management of dialysis and mid- to late-stage chronic kidney disease (CKD) patients from the perspective of…

The need for improved AD therapeutics is considerable; current treatment options are limited, and none can cease or even delay the inexorable cognitive and functional decline caused by the disease…

Emerging Therapies: Nucala (US) is a three-wave syndicated detailed expanded analysis that specifically tracks the introduction of Nucala, the first IL-5 inhibitor approved to treat eosinophilic…

Combination therapies are transforming the malignant melanoma treatment landscape, raising the efficacy bar for emerging therapies. However, combination therapies have increased the cost of…

This three-wave syndicated report series tracks the introduction of Darzalex, a human anti-CD38 MAb, and Empliciti, a humanized anti-SLAMF7 MAb. The FDA approved these agents in November 2015 for…